Cytomegalovirus infections in transplant patients

Scandinavian Journal of Infectious Diseases, Supplement

Volumn , Issue 100, 1996, Pages 59-63

  Ljungman, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; ANTIVIRUS AGENT;

BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DEATH; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIVARIATE ANALYSIS; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; RISK; CYTOMEGALIC INCLUSION BODY DISEASE; GRAFT SURVIVAL; INCIDENCE; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL RATE;

ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; CYTOMEGALOVIRUS INFECTIONS; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; ORGAN TRANSPLANTATION; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 0029658072     PISSN: 03008878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Plotkin SA, Michelson S, eds. Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Amsterdam: Excerpta Medica International Congress Series vol. 1032: 233-240, 1993.
2. Meyers J, Flournoy N, Thomas E. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153: 478-488, 1986.
3. Meyers J, Reed E, Shepp D,.Thornquist M, Dandliker PS, Vicary CA, Flournoy N, Kirk LE, Kersey JH, Thomas, ED, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318: 70-75, 1988.
4. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez RJ, Mandelli F, Kho P, Kennedy L, Bell AR. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 343: 749-753, 1994.
5. Goodrich J, Bowden R, Fisher L, Keller C, Schoch G, Meyers J. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118: 173-178, 1993.
6. Winston D, Ho W, Bartoni K, Du Mond C, Ebeling D, Buhles W, Champlin R. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118: 179-184, 1993.
7. Bacigalupo A, Tedone E, van Lint MT, Trespi G, Lönngren M, Sanna MA, Moro F, Frassoni F, Occhini D, Gualandi F, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 13: 783-788, 1994.
8. Bass E, Powe N, Goodman S, Graziano S, Griffiths R, Kickler T, Wingard J. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 12: 273-282, 1993.
9. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Peterson FB, Witherspoon RP, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323: 705-712, 1990.
10. Meyers J, Ljungman P, Fisher L. Cytomegalovirus excretion as a predictor of CMV disease after marrow transplantation: importance of CMV viremia. J Infect Dis 162: 373-380, 1990.
11. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 324: 1005-1011, 1991.
12. Ljungman P, Aschan J, Azinge JN, Brandt L, Ehrnst A, Hammarström V, Klaesson S, Linde A, Lönnqvist B, Ringdén O, Gahrton G. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol 83: 118-124, 1993.
13. Goodrich JM, Mon M, Cleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325: 1601-1607, 1991.
14. van der Bij W, Torensma R, van Son WJ, Anema J, Schirm J, Tegzess AM, The TH. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 25: 179-188, 1988.
15. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 80: 1358-1364, 1992.
16. Ehrnst A, Barkholt L, Brattström C, Czajkowski J, Teodosiu O, Tollemar J, Ljungman P. Detection of CMV-matrix pp65 antigen in leucocytes by immunofluorescence as a marker of CMV disease. J Med Virol 39: 118-124, 1993.
17. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Müller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplant as demonstrated by the polymerase chain reaction technique. Blood 77: 1104-1110, 1991.
18. Ehrnst A, Barkholt L, Levensohhn-Fuchs I, Ljungman P, Teodosiu O, Staland Å, Ringdén O, Tydén G, Johansson B. CMV PCR monitoring in leukocytes of transplant patients. Clin Diagnost Virol 3: 139-153, 1995.
19. Vlieger A, Boland G, Jiwa N, de Weger R, Willemze R, de Gast G, Falkenburg J. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplant 9: 247-253, 1992.
20. Einsele H, Ehninger G, Hebart H, Wittkowski K, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Löffler J, Wagner S, Waller H, Müller CA. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86: 2815-2820, 1995.